94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Angela I. Schriek1Marlies M. van Haaren1Meliawati Poniman1Gillian Dekkers2Arthur E. H. Bentlage3Marloes Grobben1Gestur Vidarsson3Rogier W. Sanders1,4Theo Verrips5,6Teunis B. H. Geijtenbeek7Raimond Heukers2Neeltje A. Kootstra7Steven W. de Taeye1*Marit J. van Gils1*- 1Department of Medical Microbiology, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, Netherlands
- 2QVQ Holding BV, Utrecht, Netherlands
- 3Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
- 4Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, United States
- 5Department of Biology, Faculty of Sciences, Utrecht University, Utrecht, Netherlands
- 6VerLin BV, Utrecht, Netherlands
- 7Department of Experimental Immunology, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, Netherlands
A corrigendum on
Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
by Schriek AI, van Haaren MM, Poniman M, Dekkers G, Bentlage AEH, Grobben M, Vidarsson G, Sanders RW, Verrips T, Geijtenbeek TBH, Heukers R, Kootstra NA, de Taeye SW and van Gils MJ (2022) 13:893648. doi: 10.3389/fimmu.2022.893648
In the published article, there was an error in the Funding statement. The funder was mentioned as AIDSfonds and Aids fonds instead of Aidsfonds. The correct Funding statement appears below.
Funding
This work was supported by HealthHolland/Aidsfonds: LSHM19101/P-44802, by HealthHolland/AMC: 2019-1167 and the AMC Fellowship from Amsterdam UMC received by MJG. ST is supported by Young investigator grant P-53301 Aidsfonds.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: HIV-1, nanobodies, neutralization, Fc fusion, Fc-mediated effector functions
Citation: Schriek AI, van Haaren MM, Poniman M, Dekkers G, Bentlage AEH, Grobben M, Vidarsson G, Sanders RW, Verrips T, Geijtenbeek TBH, Heukers R, Kootstra NA, de Taeye SW and van Gils MJ (2022) Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions. Front. Immunol. 13:1091668. doi: 10.3389/fimmu.2022.1091668
Received: 07 November 2022; Accepted: 09 November 2022;
Published: 22 November 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Schriek, van Haaren, Poniman, Dekkers, Bentlage, Grobben, Vidarsson, Sanders, Verrips, Geijtenbeek, Heukers, Kootstra, de Taeye and van Gils. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marit J. van Gils, m.j.vangils@amsterdamumc.nl; Steven W. de Taeye, s.w.detaeye@amsterdamumc.nl